Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals

Mechanisms of Ageing and Development

Volumn 132, Issue 11-12, 2011, Pages 583-587

  Beeri, Michal Schnaider ^a,b   Moshier, Erin ^a   Schmeidler, James ^a   Godbold, James ^a   Uribarri, Jaime ^a   Reddy, Sarah ^a   Sano, Mary ^a,b   Grossman, Hillel T ^a   Cai, Weijing ^a   Vlassara, Helen ^a   Silverman, Jeremy M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Alzheimer's disease; Cognitive decline; Methylglyoxal; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN E4; METHYLGLYOXAL;

AGE; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; AGING; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; NEUROTOXINS; PYRUVALDEHYDE; REGRESSION ANALYSIS;

EID: 84855887867     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2011.10.007     Document Type: Article

References (39)

1. Ahmed N., et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 2005, 92(January (2)):255-263.
2. Bar K.J., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol. Aging 2003, 24(March (2)):333-338.
3. Beeri M.S., et al. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006, 67(September (6)):1006-1010.
4. Beeri M.S., et al. Coronary artery disease is associated with Alzheimer disease neuropathology in ApoE4 carriers. Neurology 2006, 66(May (9)):1399-1404.
5. Beeri M.S., et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008, 71(September (10)):750-757.
6. Brouwers O., et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010, 53(May (5)):989-1000.
7. Cai W., et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol. Med. 2002, 8(July (7)):337-346.
8. Carrion-Baralt J.R., et al. Impact of APOE epsilon4 on the cognitive performance of a sample of non-demented Puerto Rican nonagenarians. J. Alzheimers Dis. 2009, 18(3):533-540.
9. Cerami A., Vlassara H., Brownlee M. Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism. 1985, 34(December (12 Suppl. 1)):37-42.
10. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
11. Corrada M.M., et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann. Neurol. 2010, 67(January (1)):114-121.
12. de Arriba S.G., et al. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells - protection by carbonyl scavengers. Neurobiol. Aging 2007, 28(July (7)):1044-1050.
13. Dickson D.W., et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol. Aging 1996, 17(September (5)):733-743.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(June (6)):499-502.
15. Goldstein D.E., et al. Tests of glycemia in diabetes. Diabetes Care 2003, 26(January (Suppl. 1)):S106-S108.
16. Hall C.B., et al. Education delays accelerated decline on a memory test in persons who develop dementia. Neurology 2007, 69(October (17)):1657-1664.
17. Kilhovd B.K., et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007, 50(July (7)):1409-1417.
18. Kinsella K., Velkoff V.A. Life expectancy and changing mortality. Aging Clin. Exp. Res. 2002, 14(October (5)):322-332.
19. Kuhla B., et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2005, 1043(June):211-216.
20. Luchsinger J.A., Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr. Atheroscler. Rep. 2004, 6(July (4)):261-266.
21. Maeta K., et al. Diagnosis of cell death induced by methylglyoxal, a metabolite derived from glycolysis, in Saccharomyces cerevisiae. FEMS Microbiol. Lett. 2005, 243(February (1)):87-92.
22. Meli M., et al. Serum pentosidine as an indicator of Alzheimer's disease. J. Alzheimers Dis. 2002, 4(April (2)):93-96.
23. Munch G., et al. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural Transm. 1998, 105(4-5):439-461.
24. Nobecourt E., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 2010, 30(April (4)):766-772.
25. Ossendorf M., Prellwitz W. Rapid and easy apolipoprotein E genotyping using an improved PCR-RFLP technique. Qiagen 2000, (January):11-13.
26. Ramasamy R., Yan S.F., Schmidt A.M. Methylglyoxal comes of AGE. Cell 2006, 124(January (2)):258-260.
27. Schnaider B.M., et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004, 63(November (10)):1902-1907.
28. Shuvaev V.V., et al. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 2001, 22(May (3)):397-402.
29. Thornalley P.J. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 2003, 31(December (Pt 6)):1343-1348.
30. Twisk J., Rijmen F. Longitudinal Tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. J. Clin. Epidemiol. 2009, 62:953-958.
31. van den B.E., et al. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006, 49(September (9)):2015-2023.
32. Vitek M.P., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(May (11)):4766-4770.
33. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 1994, 70(February (2)):138-151.
34. Vlassara H., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(November (24)):15596-15601.
35. Webster J., et al. The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox. Res. 2005, 7(1-2):95-101.
36. Weisman D., Hakimian E., Ho G.J. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam. Horm. 2006, 74:505-530.
37. Woltjer R.L., et al. Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J. Alzheimers Dis. 2003, 5(December (6)):467-476.
38. Yan S.D., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382(August (6593)):685-691.
39. Yao D., et al. Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell 2006, 124(January (2)):275-286.